The 11th International AIDS Society Conference on HIV Science

Download All
July 18-21, 2021; Virtual
CCO is the official provider of online scientific analysis for IAS 2021 through rapid post-conference webinars by expert faculty, Capsule Summaries, downloadable slides, podcasts, and ClinicalThought commentaries.
Jennifer Cocohoba Headshot
Jennifer Cocohoba, PharmD
Adeeba Kamarulzaman, MBBS, FRACP, FASc
Daniel R. Kuritzkes, MD
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
person default
Jason Schafer, PharmD, MPH
Babafemi Taiwo, MBBS

Highlights

Key studies to be presented at the 11th IAS Conference on HIV Science, from International Co-Chair and IAS President, Dr. Adeeba Kamarulzaman

Adeeba Kamarulzaman, MBBS, FRACP, FASc Released: July 19, 2021

Not sure how to interpret conflicting results in studies of HIV and SARS-CoV-2 coinfection? Dr. Daniel R. Kuritzkes discusses new results of studies of people with HIV and COVID-19, presented at IAS 2021.

Daniel R. Kuritzkes, MD Released: August 20, 2021

Listen to expert insights from Babafemi Taiwo, MBBS, on updates from IAS 2021, including new data on COVID-19 and HIV, 2-drug ART, long-acting injectable ART, investigational agents, and new therapies for multidrug-resistant tuberculosis.

Babafemi Taiwo, MBBS Released: August 19, 2021

Hear insights from Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, on exciting new data from IAS 2021, including 2-drug regimens for ART, long-acting ART, and novel antiretrovirals, and learn how these new data influence the role of the pharmacist in caring for patients with HIV.

Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD person default Jason Schafer, PharmD, MPH Released: August 23, 2021

Read expert faculty members’ summaries of key studies from this important annual conference, including new data on the following hot topics: HIV PrEP; 2-drug regimen ART; ART in children and adolescents; long-acting ART; investigational ART; treatment strategies for cryptococcal meningitis and drug resistant tuberculosis; and COVID-19 outcomes in people with HIV.

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: August 5, 2021

Hear unique insights from CCO’s expert faculty, Dr. Chloe Orkin, as she presents her insights on some of the most clinically relevant new data presented at IAS 2021, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB + RPV for ART in treatment-naive PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: August 9, 2021

Hear unique insights from CCO’s expert faculty, Dr. Daniel Kuritzkes, as he presents his insights on some of the most clinically relevant new data presented at IAS 2021, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB + RPV for ART in treatment-naive PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.

Daniel R. Kuritzkes, MD Released: August 9, 2021

Hear unique insights from CCO’s expert faculty, Dr. Babafemi Taiwo, as he presents his insights on some of the most clinically relevant new data presented at IAS 2021, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB + RPV for ART in treatment-naive PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.

Babafemi Taiwo, MBBS Released: August 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue